Biotech Values

[ghmm]

Why is this significant? While it certainly could be a scheduling conflict I don't think so! First this is during the day and not at the close. Since JJ Bienaime took the helm I believe all quarterly calls have been at 5PM, the only ones during the day have been announcements. The company is due to announce results from their 2A study in poorly controlled hypertension (6R-BH4) any day now so my guess is that is what will happen then. So lets see according to Dew's logic if there is negative news you want to do it on a Friday night, so positive news would be done when? While everyone is expecting the company to be sold this year, I am not convinced of them being sold soon (just my opinion).
[Edit] Mistaken the first couple of calls when JJ took over were at 12:00 but none since.

http://biz.yahoo.com/prnews/070216/sff023.html?.v=81

BioMarin Announces Date and Time Change of Fourth Quarter and Full Year 2006 Financial Results Conference Call and Webcast to Tuesday, February 20 at 11:00 a.m. ET (17:00 CET)
Friday February 16, 4:00 pm ET

NOVATO, Calif., Feb. 16 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN - News News) today announced that it has changed the date and time of its fourth quarter and full year 2006 financial results conference call and webcast from Thursday, February 22 at 5:00 p.m. ET (23:00 CET) to Tuesday, February 20, at 11:00 a.m. ET (17:00 CET).

What: BioMarin Fourth Quarter and Full Year 2006 Earnings Call and Webcast
When: Tuesday, February 20, 2007 at 11:00 a.m. ET (17:00 CET)
U.S. / Canada Dial-in Number: 800.901.5217
International Dial-in Number: 617.786.2964
Participant Code: 35915200
Replay Dial-in Number: 888.286.8010
Replay International Dial-in Number: 617.801.6888
Replay Code: 94899251

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for at least one week following the call.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin, and Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation. Investigational product candidates include Phenoptin(TM) (sapropterin dihydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU), and 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of poorly controlled hypertension and peripheral arterial disease. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Naglazyme® is a registered trademark of BioMarin Pharmaceutical Inc.
Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors and Media
Eugenia Shen
BioMarin Pharmaceutical Inc.
415-506-6570